Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations

被引：0
|
作者：
G. Ragnarson Tennvall
J. Apelqvist
机构：
[1] IHE,
[2] the Swedish Institute for Health Economics,undefined
[3] Lund,undefined
[4] Sweden,undefined
[5] Department of Internal Medicine,undefined
[6] Lund University Hospital,undefined
[7] Lund,undefined
[8] Sweden,undefined
来源：
Diabetologia | 2001年 / 44卷
关键词：
Keywords Prevention, markov analysis, model simulation, amputation, foot ulcer, cost, cost-effective, cost-saving, quality of life.;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2077 / 2087
页数：10
相关论文
共 50 条
  • [41] Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe-The HEALTH Model
    Schwander, Bjoern
    Gradl, Birgit
    Zoellner, York
    Lindgren, Peter
    Diener, Hans-Christoph
    Lueders, Stephan
    Schrader, Joachim
    Antonanzas Villar, Fernando
    Greiner, Wolfgang
    Jonsson, Bengt
    VALUE IN HEALTH, 2009, 12 (06) : 857 - 871
  • [42] Cost-utility analysis of an integrated care model for multimorbid patients based on a clinical trial
    Lanzeta, Itziar
    Mar, Javier
    Arrospide, Arantzazu
    GACETA SANITARIA, 2016, 30 (05) : 352 - 358
  • [43] Antibacterial-Integrated Collagen Wound Dressing for Diabetes-Related Foot Ulcers: An Evidence-Based Review of Clinical Studies
    N. Amirrah, Ibrahim
    Mohd Razip Wee, Mohd Farhanulhakim
    Tabata, Yasuhiko
    Bt Hj Idrus, Ruszymah
    Nordin, Abid
    Fauzi, Mh Busra
    POLYMERS, 2020, 12 (09)
  • [44] Empagliflozin in Type 2 Diabetes Mellitus Patients with High Cardiovascular Risk: A Model-Based Cost-Utility Analysis in China
    Men, Peng
    Liu, Tianbi
    Zhai, Suodi
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 2823 - 2831
  • [45] COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL
    Nguyen, C. M.
    Mendes, M.
    Bounthavong, M.
    Christopher, M.
    Morreale, A. P.
    VALUE IN HEALTH, 2010, 13 (03) : A127 - A128
  • [46] Cost-utility analysis using a Markov model to compare prescription statins versus potential over the counter statins in USA
    Gandhi, P. K.
    McGhan, W. F.
    Peterson, A. M.
    VALUE IN HEALTH, 2006, 9 (06) : A352 - A352
  • [47] COST-UTILITY ANALYSIS OF POLYGENIC RISK SCORE IN THE PREVENTION OF TYPE 2 DIABETES AN OBJECT-ORIENTED INDIVIDUAL-LEVEL MODEL WITH PROBABILISTIC SENSITIVITY ANALYSIS
    Martikainen, J. A.
    Lehtimaki, A., V
    Jalkanen, K.
    Lavikainen, P.
    Paajanen, T.
    Marjonen, H.
    Kristiansson, K.
    Lindstrom, J.
    Perola, M.
    VALUE IN HEALTH, 2022, 25 (12) : S117 - S117
  • [48] Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China
    Hu, Shanshan
    Su, Xiaorong
    Deng, Xun
    Wang, Yong
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [49] Australian guideline on wound healing interventions to enhance healing of foot ulcers: part of the 2021 Australian evidence-based guidelines for diabetes-related foot disease
    Pamela Chen
    Keryln Carville
    Terry Swanson
    Peter A. Lazzarini
    James Charles
    Jane Cheney
    Jenny Prentice
    Journal of Foot and Ankle Research, 15
  • [50] Cost Effectiveness of Ibandronate for the Prevention of Fractures in Inflammatory Bowel Disease-Related OsteoporosisCost-Utility Analysis Using a Markov Model
    Simon Kreck
    Jochen Klaus
    Reiner Leidl
    Christian von Tirpitz
    Alexander Konnopka
    Herbert Matschinger
    Hans-Helmut König
    PharmacoEconomics, 2008, 26 : 311 - 328
12345